Credit Suisse Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $185

Credit Suisse maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $201 to $185.

Benzinga · 11/08/2019 14:48

Credit Suisse maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $201 to $185.